A detailed multi-omics assessment of BRCA1 and BRCA2 mutant mouse models of breast cancer revealed that this difference in sensitivity to immunotherapy is driven, at least in part, by the quality of the immune infiltrate. Here, BRCA1 is linked to breast cancer.